Recruiting
Phase 2
Phase 3

EXV-802 & EXV-801

Sponsor:

Exciva GmbH

Code:

NCT07284472

Conditions

Agitation Associated With Alzheimer's Disease Dementia

Eligibility Criteria

Sex: All

Age: 55 - 70+

Healthy Volunteers: Not accepted

Interventions

EXV-802

Placebo

EXV-801

Study Details

Brief summary:

The goal of this clinical trial is to evaluate the safety and efficacy of EXV-802 and EXV-801 in treatment of agitation in participants with Alzheimer's Disease dementia.

Conditions

Agitation Associated With Alzheimer's Disease Dementia

Study ID

NCT07284472

Start date

Feb 2, 2026

Status verified date

Aug, 2026

Completion date

Feb, 2029

Anticipated

Primary completion date

Jan, 2029

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 55 - 70+

Healthy Volunteers: Not accepted

Inclusion criteria:

1. The participant is an adult male or female between the ages of 55 to 90 years inclusively, who can move around by themselves, with a walker or a wheelchair.
2. A previously established diagnosis of AD dementia.
3. The participant has clinically significant, moderate/severe agitation at the time of screening and for at least 2 weeks prior to randomization
4. The diagnosis of agitation must meet the International Psychogeriatric Association (IPA) provisional definition of agitation.
5. Caregiver who is able and willing to comply with all required study procedures and who is in contact with the participant at least on four individual days for at least two hours per day.

Exclusion criteria:

1. The participant has a confirmed primary diagnosis of a dementia-related disease other than AD dementia.
2. The participant has symptoms of agitation that are not secondary to AD dementia
3. The participant has a history of uncontrolled seizures or a history of epilepsy.
4. The participant has a major medical illness or unstable medical condition

Study Design

Enrollment

300 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: EXV-802

Participants will be assigned to treatment with EXV-802 capsules administered twice a day over a 6-week period.

placebo comparator: Placebo

Participants will be assigned to treatment with placebo capsules administered twice a day over a 6-week period.

experimental: EXV-801

Participants will be assigned to treatment with EXV-801 capsules administered twice a day over a 6-week period.

Interventions

EXV-802

Specified dose twice daily

Placebo

Specified dose twice daily

EXV-801

Specified dose twice daily

Primary outcome measure

  • Changes from baseline to endpoint (Week 6) in the Cohen-Mansfield Agitation Inventory - International Psychogeriatric Association (CMAI-IPA) score [ Time Frame: Baseline to Week 6 ]

Central Contacts and Locations

Central contacts

Locations

Esperanza Clinical

Recruiting

Murrieta, California, United States, 92562

Josephson Wallack Munshower Neurology PC

Recruiting

Indianapolis, Indiana, United States, 46260

Precise Research Centers

Recruiting

Flowood, Mississippi, United States, 39232

Integrative Clinical Trials

Recruiting

Brooklyn, New York, United States, 11229

Manhattan Behavioral Medicine

Recruiting

New York, New York, United States, 10036

Insight Clinical Trials

Recruiting

Independence, Ohio, United States, 44131

The Memory Clinic

Recruiting

Bennington, Vermont, United States, 05201

Kawartha Centre

Recruiting

Peterborough, Ontario, Canada, K9H 294

More Information

Sponsor

Exciva GmbH

Last update posted

Aug 14, 2026

Last verified

Aug, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Exciva GmbH on 2026-08-14.